Victory Capital Management
ALLO icon

Victory Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Victory Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.8K Sell
17,119
-1,333
-7% -$2.67K ﹤0.01% 2326
2025
Q4 		$25.3K Buy
18,452
+840
+5% +$1.11K ﹤0.01% 2371
2025
Q3 		$21.8K Sell
17,612
-212
-1% -$253 ﹤0.01% 2391
2025
Q2 		$20.1K Buy
17,824
+1,563
+10% +$2.08K ﹤0.01% 2442
2025
Q1 		$23.7K Sell
16,261
-1,380
-8% -$2.6K ﹤0.01% 2420
2024
Q4 		$37.6K Buy
17,641
+262
+2% +$646 ﹤0.01% 2414
2024
Q3 		$48.7K Sell
17,379
-318
-2% -$848 ﹤0.01% 2394
2024
Q2 		$41.2K Buy
17,697
+4,022
+29% +$11.9K ﹤0.01% 2383
2024
Q1 		$61.1K Sell
13,675
-608
-4% -$2.54K ﹤0.01% 2358
2023
Q4 		$45.8K Buy
14,283
+2,680
+23% +$7.6K ﹤0.01% 2446
2023
Q3 		$36.8K Buy
+11,603
New +$50.8K ﹤0.01% 2406
2022
Q3 		– Sell
-14,525
Closed -$166K – 2701
2022
Q2 		$166K Buy
14,525
+190
+1% +$1.69K ﹤0.01% 2391
2022
Q1 		$120K Buy
14,335
+1,688
+13% +$17.6K ﹤0.01% 2492
2021
Q4 		$189K Sell
12,647
-363
-3% -$6.41K ﹤0.01% 2493
2021
Q3 		$334K Sell
13,010
-47,258
-78% -$1.12M ﹤0.01% 2346
2021
Q2 		$1.57M Sell
60,268
-888,591
-94% -$25.3M ﹤0.01% 1704
2021
Q1 		$33.5M Sell
948,859
-67,193
-7% -$2.27M 0.03% 719
2020
Q4 		$25.6M Sell
1,016,052
-195,611
-16% -$6.38M 0.03% 773
2020
Q3 		$45.7M Buy
1,211,663
+143,215
+13% +$5.4M 0.06% 493
2020
Q2 		$45.8M Buy
1,068,448
+1,048,110
+5,153% +$37.9M 0.06% 452
2020
Q1 		$396K Buy
20,338
+7,974
+64% +$190K ﹤0.01% 2160
2019
Q4 		$321K Buy
12,364
+3,610
+41% +$99.4K ﹤0.01% 2182
2019
Q3 		$239K Buy
+8,754
New +$249K ﹤0.01% 2159

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management's ALLO Position: Q1 2026 in Review

Victory Capital Management reduced its Allogene Therapeutics (ALLO) stake by 7.2% in Q1 2026, selling an estimated $2.67K and leaving 17,119 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Victory Capital Management first reported a position in ALLO in Q3 2019 and has held it in 23 quarters since. The position peaked at $45.8M in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Victory Capital Management held 17,119 shares of Allogene Therapeutics worth $41.8K as of Q1 2026.
  • Victory Capital Management sold 1,333 Allogene Therapeutics shares in Q1 2026, an estimated $2.67K.
  • Allogene Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2326 holding.
  • Victory Capital Management first reported a position in Allogene Therapeutics in Q3 2019 and has held it in 23 quarters since.
  • Victory Capital Management's Allogene Therapeutics position peaked at $45.8M in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.